Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIST+: Intranasal Steroid for Sleep-Disordered Breathing in Children
NCT05382494Phase 4Completed
- Sponsor
- Murdoch Children's Research Institute
- Start
- Dec 2022
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of mometasone furoate nasal spray in sleep disordered breathing (SDB) (2 arms), sponsored by Murdoch Children's Research Institute. Primary endpoint: Proportion of participants with resolution of significant Sleep Disordered Breathing (SDB) symptoms at 6 weeks. Started Dec 2022; status: completed.
02
Drugs
mometasone furoate nasal spray
03
Conditions
sleep disordered breathing (SDB)
Beyond the preview
Go deeper on NCT05382494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05382494.